Skip to main content
. 2015 Jul 23;4:59–68. doi: 10.1016/j.bbacli.2015.07.001

Fig. 6.

Fig. 6

Role of GSK3α/β on AKT suppression of FOXO3A and PKCδ in AML cell lines. (A) Protein lysate (200,000 cell equivalents) from OCI-AML3 cells containing control (NS) lentiviral plasmid or cells containing FOXO3A shRNA using 2 different lentiviral plasmids, and THP-1 cells or HL60 cells containing control (NS) lentiviral plasmid or cells containing PKCδ shRNA lentiviral plasmid were subject to SDS/PAGE and Western analysis performed for GSK3α/β, phosphorylated GSK3α/β, PKC d, FOXO3A, MYC, and Tubulin. Ratios were determined by densitometric analysis of the bands depicted in the figure and normalized to each NS control. (B) Protein lysate (200,000 cell equivalents) from OCI-AML3 cells treated with vehicle (-/-; 0.1 % DMS) or Calbiochem GSK3 inhibitor XVI (5 μM) or MK-2206 AKT inhibitor (1 μM) for 6 h were subject to SDS/PAGE and Western analysis performed for GSK3α/β, phosphorylated GSK3α/β, PKCδ, phosphorylated PKCδ, and Tubulin. Ratios were determined by densitometric analysis of the bands depicted in the figure and normalized to vehicle treated control.